Extended-spectrum β-lactamases and clinical outcomes: Current data

Clinical Infectious Diseases

Volumn 42, Issue SUPPL. 4, 2006, Pages

  Ramphal, Reuben ^a   Ambrose, Paul G ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIUM CARRIER; CLINICAL TRIAL; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NEWBORN INFECTION; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEPSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; TREATMENT OUTCOME;

EID: 33645788333     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/500663     Document Type: Review

References (56)

1. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6:460-3.
2. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-12.
3. Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002; 34:135-46.
4. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, beta- lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001; 21:583-92.
5. Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28:1718-23.
6. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174:529-36.
7. Yoon CJ, Behta M, Zuccotti GJ. Extended-spectrum β-lactamase (ESBL) producing Klebsiella pneumoniae bacteremia: risk factors and outcome [abstract 95]. Presented at the 39th Annual Meeting of the Infectious Disease Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001.
8. Chemaly RF, Hall GS, Long J, Tuohy M, Procop GW, Gordon SM. Clinical and microbiological significance of blood stream infection due to ESBL-producing Klebsiella pneumoniae: a case-control study [abstract 96]. Presented at the 39th Annual Meeting of the Infectious Disease Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001.
9. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002; 52:99-106.
10. Emery CL, Weymouth LA. Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35:2061-7.
11. Ariffin H, Navaratnam P, Mohamed M, et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 2000; 4:21-5.
12. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46:1481-91.
13. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34:567-73.
14. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990; 34:2193-9.
15. Smith CE, Tillman BS, Howell AW, Longfield RN, Jorgensen JH. Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum β-lactamase. Antimicrob Agents Chemother 1990; 34:1290-3.
16. Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989; 33:1451-6.
17. Ma L, Ishii Y, Chang FY, Yamaguchi K, Ho M, Siu LK. CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum β-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother 2002; 46:1985-8.
18. Rasheed JK, Anderson GJ, Queenan AM, et al. TEM-71, a novel plasmid-encoded, extended-spectrum β-lactamase produced by a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2002; 46:2000-3.
19. NCCLS. Performance standards for antimicrobial susceptibility testing. 14th Informational supplement. NCCLS document M100-S14. Wayne, PA: NCCLS, 2004.
20. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38:409-24.
21. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987; 2:302-6.
22. Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum beta-lactamase. J Antimicrob Chemother 1996; 37:203-4.
23. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23:118-24.
24. Craig WA, Bhavnani SM, Ambrose PG. The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis 2004; 50:229-30.
25. Andes D, Craig WA. Impact of extended-spectrum beta-lactamase production on the activity of cefepime in a murine-thigh infection model [abstract 1099]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
26. Maglio D, Ong C, Banevicius MA, Geng Q, Nightingale CH, Nicolau DP. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-β-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 2004; 48:1941-7.
27. Ambrose PG, Bhavnani SM, Jones RN, Craig WA, Dudley MN. Use of pharmacokinetics-pharmacodynamics and Monte Carlo simulation as decision support for the re-evaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae [poster A-138]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
28. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119:353-8.
29. Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001; 41:183-9.
30. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003; 45:279-85.
31. Garcia-Rodriguez JA, Jones RN. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme. J Chemother 2002; 14:25-32.
32. Pfaller MA, Jones RN, Biedenbach DJ. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis 2001; 41:177-82.
33. Mathai D, Lewis MT, Kugler KC, Pfaller MA, Jones RN. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia. I. Results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis 2001; 39:105-16.
34. Roland RK, Mendes RE, Silbert S, Bolsoni AP, Sader HS. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams. Braz J Infect Dis 2000; 4:226-35.
35. Pillay T, Pillay DG, Adhikari M, Sturm AW. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am J Perinatol 1998; 15:47-51.
36. Jones RN, Pfaller MA. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum β-lactamase in Europe. Clin Microbiol Infect 2003; 9:708-12.
37. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32(Suppl 2):S94-103.
38. Szabo D, Mathe A, Lengyel J, Anderlik P, Rokusz L, Rozgonvi F. In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain. Curr Med Chem 2002; 9:437-42.
39. Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother 2001; 48:37-45.
40. Gales AC, Bolmstrom A, Sampaio J, Jones RN, Sader HS. Antimicrobial susceptibility of Klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL) isolated in hospitals in Brazil. Braz J Infect Dis 1997; 1:196-203.
41. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30:473-8.
42. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G. Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46:196-202.
43. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN. Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 2002; 42:193-8.
44. Yu WL, Jones RN, Hollis RJ, et al. Molecular epidemiology of extended-spectrum β-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002; 40:4666-9.
45. Quale JM, Landman D, Bradford PA, et al. Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 2002; 35:834-41.
46. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33:1288-94.
47. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 2003; 21:1-7.
48. Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002; 49:445-53.
49. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST Program. Antimicrob Agents Chemother 2003; 47:1643-6.
50. Goethaert K, Jansens H, Van Looveren M, et al. Cefepime for the treatment of infections due to ESBL-producing Enterobacter aerogenes [abstract K-718]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003.
51. Ramphal R, Bille J, Yigit H, et al. Outcomes of infections caused by extended spectrum beta-lactamase (ESBL) producing strains of E. coli and Klebsiella spp. treated with cefepime [abstract O275]. In: Programs and abstracts of the 12th European Congress of Clinical Microbiology and Infectious Diseases (Milan). Basel: European Society of Clinical Microbiology and Infectious Diseases, 2002:42.
52. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-7.
53. Empey KM, Rapp RP, Evans ME. The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy 2002; 22:81-7.
54. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280:1233-7.
55. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002; 23:106-8.
56. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.